Generic immunosuppression in solid organ transplantation: a Canadian perspective

Area of Science:

• Transplantation immunology
• Pharmacoeconomics
• Drug safety

Background:

• Generic immunosuppressants may reduce costs in solid organ transplantation (SOT).
• Ensuring therapeutic equivalence between generic and branded immunosuppressants is crucial for patient outcomes.
• Current regulatory standards (bioequivalence in healthy volunteers) may not guarantee equivalence in SOT recipients.

Purpose of the Study:

• To develop recommendations on the use of generic immunosuppression in SOT recipients.
• To review available data on the clinical outcomes of generic immunosuppressants.
• To identify potential risks and challenges associated with generic immunosuppressive drug use.

Main Methods:

• Review of available scientific literature and clinical data.
• Analysis of Health Canada licensing requirements for generic drugs.
• Expert consensus development by an interprofessional working group.

Main Results:

• Limited published evidence supports the therapeutic equivalence of generic immunosuppressants in SOT recipients.
• Cyclosporine, tacrolimus, and sirolimus are critical dose drugs, requiring strict monitoring.
• Uncontrolled product switching between different generic formulations poses a significant patient safety risk.

Conclusions:

• Caution is warranted regarding the use of generic immunosuppressive drugs in SOT.
• Robust clinical data and adequate regulatory safeguards are needed.
• New practices, including intensive monitoring and patient education, are essential to mitigate risks.